There are a number of clauses in there.
First of all, there is the one about patent term extension. Currently, patents are valid for 20 years from the date of filing. The TPP doesn't give a number, it would probably add two years of patent life, which means that would delay generic drugs coming on the market for two years. I would get rid of that.
There is a provision there that allows drug companies to continue to market their products through their websites to consumers. If you look at information from the United States, you can see that there are a large number of warning letters that the U.S. Food and Drug Administration has to send to these companies because they either don't mention safety information or they exaggerate the effectiveness. I would eliminate that clause in this agreement.
I would also carve out pharmaceuticals from the ISDS provisions so that companies could not do what Eli Lilly, for instance, is doing right now.